(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

The trial enrolled patients with cryptogenic stroke and evidence suggestive of atrial cardiopathy, but no evidence of atrial fibrillation, who were randomized to apixaban, 5 mg or 2.5 mg twice daily, ...

The long-term adverse effects of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, are well ...

Bologna 8 April 2022 - Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated ...

TAHO Pharma submits NDA to US FDA for TAH3311, the world’s first apixaban oral dissolving film: Taipei, Taiwan Friday, October 3, 2025, 12:00 Hrs [IST] TAHO Pharmaceuticals Ltd.